Today, the COVAX Facility announced it has now delivered vaccines to 100 countries in the space of just 42 days since the first doses arrived in Ghana on 24 February.
This includes more than 38 million doses, more than 37 million of which are AstraZeneca’s vaccine, which are now helping to protect the most vulnerable populations around the world. Of the 100 countries reached, 60 are among the lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment.
COVAX expects to deliver doses to all participating countries that have requested vaccines in the first half of this year. Together with its sublicense partner the Serum Institute of India (SII), hundreds of millions of doses of AstraZeneca’s vaccine are planned to be supplied to 142 countries through COVAX.
AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020, in line with the Company’s shared commitment to global, equitable access to vaccines. Over 80% of AstraZeneca doses delivered through COVAX have been to lower and middle-income countries, helping to protect the most vulnerable populations globally regardless of income level.
Pascal Soriot, CEO of AstraZeneca, said: “Today marks a significant milestone in the global fight against the pandemic as 100 countries have received vaccines through COVAX. I am proud that the supply of our vaccine accounts for the vast majority of doses being delivered through COVAX in the first half of this year. Over 37 million doses of our vaccine have been delivered to date which are protecting the most vulnerable populations around the world. Together with our COVAX partners, we continue to work 24/7 to deliver on our unwavering commitment to broad, equitable and affordable access.”
Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, added: “COVAX may be on track to deliver to all participating economies in the first half of the year yet we still face a daunting challenge as we seek to end the acute stage of the pandemic: we will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers.”
“This is a significant milestone in the fight against COVID-19. Faced with the rapid spread of COVID-19 variants, global access to vaccines is fundamentally important to reduce the prevalence of the disease, slow down viral mutation, and hasten the end of the pandemic,” said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI).
Veeva ID: Z4-32269
Date of Preparation: April 2021